TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16818280

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 or 1.3 mg/m2 administered intravenously twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles plus oral dexamethasone 20 mg on the day of and after each bortezomib dose
Number of subjects: 256

Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 256
Study: 14585874

Group type: EXPERIMENTAL
Intervention: 40 g human albumin
Number of subjects: 976

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 976
Study: 10714140

Group type: EXPERIMENTAL
Intervention: Inference learning task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard classification learning task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of stimuli during learning
Number of subjects: 0
Study: 8772600

Group type: EXPERIMENTAL
Intervention: Physiological hyperinsulinemia (0.67 vs. 2.00 mU/kg.min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Higher degrees of physiological hyperinsulinemia
Number of subjects: 27
Study: 1425271

Group type: EXPERIMENTAL
Intervention: Glucose only (2 mg/kg.min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucose+xylitol (1 mg/kg.min each)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucose-containing electrolyte solution (0.83 mg/kg.min glucose)
Number of subjects: 18
Study: 6420383

Group type: EXPERIMENTAL
Intervention: Indomethacin (500 mg/3 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31340623

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF
Number of subjects: 60

Group type: COMPARATOR
Intervention: rhG‐CSF
Number of subjects: 60
Study: 29517675

Group type: EXPERIMENTAL
Intervention: Shenmai (SM) injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% glucose (G)
Number of subjects: 40
Study: 26990509

Group type: EXPERIMENTAL
Intervention: Early precut sphincterotomy (Group A)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Repeated papillary cannulation attempts followed by late precut (Group B)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 375
Study: 24759827

Group type: EXPERIMENTAL
Intervention: Early ART (initiated 2 weeks after tuberculosis treatment onset)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Late ART (initiated 8 weeks after tuberculosis treatment onset)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 661
Study: 22531338

Group type: EXPERIMENTAL
Intervention: Transfusion of 40-day stored autologous leukoreduced packed erythrocytes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transfusion of 3-day stored autologous leukoreduced packed erythrocytes
Number of subjects: 10
Study: 21300002

Group type: EXPERIMENTAL
Intervention: Subarachnoid hemorrhage treatment (coiling, clipping)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of SAH patients (coiled, clipped, perimesencephalic hemorrhage)
Number of subjects: 77
Study: 17659645

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study: 16136270

Group type: EXPERIMENTAL
Intervention: DAART (early home-based physiotherapy intervention)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: STRETCH (group-based exercise and psychosocial intervention)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 275
Study: 11856927

Group type: EXPERIMENTAL
Intervention: Neutral position casting
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pronated position casting
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Supinated position casting
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Overall (all positions)
Number of subjects: 99
Study: 10100390

Group type: EXPERIMENTAL
Intervention: Word frequency, repetition, and lexicality effects in word recognition tasks
Number of subjects: 0
Study: 7790471

Group type: EXPERIMENTAL
Intervention: FAN bottles
Number of subjects: 6847

Group type: COMPARATOR
Intervention: Standard aerobic BacT/Alert bottles
Number of subjects: 6847

Group type: EXPERIMENTAL
Intervention: FAN bottles (subset of patients on antimicrobial therapy)
Number of subjects: 6847
Study: 2359309

Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups (MI and Control)
Number of subjects: 114
Study: 7390390

Group type: EXPERIMENTAL
Intervention: Domperidon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromoprid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 30122341

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 173

Group type: COMPARATOR
Intervention: 10 mg atorvastatin
Number of subjects: 173
Study: 28248974

Group type: EXPERIMENTAL
Intervention: Green environment exposure (Collserola Natural Park)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Blue environment exposure (Castelldefels beach)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Urban environment exposure (Eixample neighbourhood)
Number of subjects: 26
Study: 25946708

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GMTZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensification II (cytarabine/mitoxantrone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction I (cytarabine/daunorubicin/etoposide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher AML risk group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 0
Study: 24111288

Group type: EXPERIMENTAL
Intervention: Head care robot
Number of subjects: 54

Group type: COMPARATOR
Intervention: Human nurse head care
Number of subjects: 54
Study: 21327725

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg (R group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus fenofibrate 200 mg (RF group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus n-3 fatty acids 2 g (RN group)
Number of subjects: 90
Study: 19235193

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 84
Study: 16614537

Group type: EXPERIMENTAL
Intervention: Vitamin B6 1,200 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mianserin 15 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15610312

Group type: EXPERIMENTAL
Intervention: Intralesional steroid injection (8 mg triamcinolone acetate into each quadrant)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (SGBD only)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Total periodic dilatation index in study group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Total periodic dilatation index in control group
Number of subjects: 21
Study: 11730397

Group type: EXPERIMENTAL
Intervention: Low-protein diet plus resistance training (n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Low-protein diet alone (n = 12)
Number of subjects: 26
Study: 9164424

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg/day, mean 102 +/- 44 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine (20-50 mg/day, mean 36 +/- 13 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluvoxamine vs Paroxetine
Number of subjects: 60
Study: 7969676

Group type: EXPERIMENTAL
Intervention: Cysts of proximal origin (38 cysts)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cysts of undetermined origin (12 cysts)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with proximal cysts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50
Study: 2884494

Group type: EXPERIMENTAL
Intervention: Solid-phase radioimmunoassay for antibodies against neutrophil cytoplasm
Number of subjects: 0
Study: 29370818

Group type: EXPERIMENTAL
Intervention: 16-week group-based moderate-intensity stepping exercise
Number of subjects: 224

Group type: COMPARATOR
Intervention: 16-week health education
Number of subjects: 224
Study: 27799299

Group type: EXPERIMENTAL
Intervention: Biobran (1 g/day), n = 16
Number of subjects: 37

Group type: COMPARATOR
Intervention: PEG IFN plus ribavirin, n = 21
Number of subjects: 37
Study: 24710641

Group type: EXPERIMENTAL
Intervention: Gliclazide-MR
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 57
Study: 22099384

Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX; 8 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20334680

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 213

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 213

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 213
Study: 19035875

Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study: 16555069

Group type: EXPERIMENTAL
Intervention: Filtek Supreme (nanofiller resin composite)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tetric Ceram (fine hybrid resin composite)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Filtek Supreme
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tetric Ceram
Number of subjects: 50
Study: 14634760

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation program + home-based computer-assisted training (114+/‐18 sessions over 12 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 11565955

Group type: EXPERIMENTAL
Intervention: Loxoribine (doses: 1 mg/kg, 5 mg/kg, 10 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9183263

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthoses (AFOs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No ankle-foot orthoses (AFOs)
Number of subjects: 12
Study: 8246057

Group type: EXPERIMENTAL
Intervention: Normal glucose levels (<= 120 mg/dl)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (> 120 mg/dl)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Normal mean glucose levels (<= 120 mg/dl) between Days 3 and 7
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Elevated mean glucose levels (> 120 mg/dl) between Days 3 and 7
Number of subjects: 616
Study: 2937659

Group type: EXPERIMENTAL
Intervention: Progesterone supplementation (P) given 12 to 15 hours and 1 hour before and 24 hours after laparoscopy (group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Human chorionic gonadotropin given 12 hours before laparoscopy (group C)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment in addition to normal IVF procedures (group A)
Number of subjects: 42
Study: 29464879

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 120
Study: 27467125

Group type: EXPERIMENTAL
Intervention: Adherence calculated as AUC (area under the curve) using a digital audio device attached to a dry powder inhaler over a 3-month period.
Number of subjects: 239
Study: 24862240

Group type: EXPERIMENTAL
Intervention: Acceptance Facilitating Intervention (AFI)
Number of subjects: 141

Group type: COMPARATOR
Intervention: No-intervention control group (CG)
Number of subjects: 141
Study: 22865548

Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) for continuous intraoperative neuromonitoring (CIONM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine intraoperative neuromonitoring (IONM)
Number of subjects: 40
Study: 20479335

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ISMN (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of sildenafil (50 mg) and ISMN (10 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 18493713

Group type: EXPERIMENTAL
Intervention: Levetiracetam (started at 250 mg qhs, increased to 1,500 mg bid as tolerated)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Levetiracetam (treatment phase lasted 4 months)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Levetiracetam (treatment for PMDD)
Number of subjects: 7
Study: 15780443

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV) given once or twice
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 83
Study: 12084594

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (100 J)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (150 J)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (200 J)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (maximum 200 J)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform
Number of subjects: 203
Study: 10627637

Group type: EXPERIMENTAL
Intervention: Intensified stem cell transplant regimen (HDCT with escalated melphalan 160 mg/m2, fractionated total body irradiation 12 Gy, and infusional etoposide 60 mg/kg)
Number of subjects: 100
Study: 7549821

Group type: EXPERIMENTAL
Intervention: Real time ultrasound
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 102
Study: 1851649

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 units b.d.
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Logiparin 2500 units daily
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Logiparin 3500 units daily
Number of subjects: 1290
Study: 6815282

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg weekly for six weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Doxycycline (single dose on day 3 of illness)
Number of subjects: 20
Study: 31769619

Group type: EXPERIMENTAL
Intervention: Adapted-Family DSME (in-home setting)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard DSME (community setting)
Number of subjects: 221
Study: 31817816

Group type: EXPERIMENTAL
Intervention: six 30 s one‐on‐one SSGs with a 2 min rest period
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: six 45 s SSGs with a 3 min rest interval
Number of subjects: 18
Study: 28742420

Group type: EXPERIMENTAL
Intervention: Customized orthodontic system (Insignia)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Noncustomized orthodontic system (Damon Q)
Number of subjects: 180
Study: 27596360

Group type: EXPERIMENTAL
Intervention: Serelaxin (75 μg/kg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 72
Study: 24401729

Group type: EXPERIMENTAL
Intervention: Internet-linked tablet computer-based intervention (the EDGE platform)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21993878

Group type: EXPERIMENTAL
Intervention: CS+ (conditioned stimulus paired with alcohol intoxication)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CS- (conditioned stimulus not paired with alcohol intoxication)
Number of subjects: 14
Study: 19444413

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 28

Group type: COMPARATOR
Intervention: No propofol therapy
Number of subjects: 28
Study: 17536071

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diane(35) Diario (35 microg ethinyl-estradiol plus 2 mg cyproterone acetate)
Number of subjects: 34
Study: 15350250

Group type: EXPERIMENTAL
Intervention: Dalteparin 2500 U, 2500 U, 5000 U, and 7500 U daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: UFH 5000 U, 5000 U, 7500 U, and 10,000 U every 12 hours
Number of subjects: 15
Study: 11772905

Group type: EXPERIMENTAL
Intervention: Culturally appropriate diabetes lifestyle intervention in family and friends (FF) groups (n = 32)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Culturally appropriate diabetes lifestyle intervention in one-on-one (OO) appointments (n = 39)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual medical care (UC) (n = 33)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combined intervention arms (FF and OO)
Number of subjects: 104
Study: 9694068

Group type: EXPERIMENTAL
Intervention: Hyaluronan levels in the synovium of patients with rheumatoid arthritis (RA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyaluronan levels in the synovium of patients with osteoarthritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyaluronan levels in the synovium of patients with traumatic injury
Number of subjects: 0
Study: 7521490

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (0.1 mg/kg in 20 min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl infusion)
Number of subjects: 13
Study: 2589674

Group type: EXPERIMENTAL
Intervention: 10 ml of agitated saline via a peripheral vein
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2 ml of air via the epidural catheter
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham injection (nothing injected)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1 ml of air via catheters accidentally inserted in epidural veins
Number of subjects: 33
Study: 790358

Group type: EXPERIMENTAL
Intervention: Gefarnate, 50 mg four times daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (dummy capsules)
Number of subjects: 45
Study: 30366235

Group type: EXPERIMENTAL
Intervention: EF/PS CCT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Verbal ability CCT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 28151991

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic profiling with clinical decision support tool (CDST)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 110
Study: 25307511

Group type: EXPERIMENTAL
Intervention: Paricalcitol therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 48
Study: 23404304

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Combined training (aerobic + resistance)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 262
Study: 20826742

Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 19514184

Group type: EXPERIMENTAL
Intervention: Intelligent-turtle massage
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional massage method
Number of subjects: 182
Study: 17695213

Group type: EXPERIMENTAL
Intervention: N-of-1 trial
Number of subjects: 1
Study: 14693964

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 60
Study: 11641676

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg) every 6 hours
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral misoprostol (50 microg) every 3 hours
Number of subjects: 126
Study: 9408917

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 +/‐ 2.5 mg/day
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 +/‐ 2.5 mg/day
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 +/‐ 2.5 mg/day
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Haloperidol 15 +/‐ 5 mg/day
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 8208968

Group type: EXPERIMENTAL
Intervention: Computer-based (video) informed consent
Number of subjects: 160

Group type: COMPARATOR
Intervention: Written informed consent
Number of subjects: 160
Study: 2543996

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30626400

Group type: EXPERIMENTAL
Intervention: P3P (Personal Patient Profile‐Prostate)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 392
Study: 27856067

Group type: EXPERIMENTAL
Intervention: PCL Retaining (PCLR) TKA
Number of subjects: 37

Group type: COMPARATOR
Intervention: PCL Substituting (PCLS) TKA
Number of subjects: 37
Study: 26141466

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 15.0 g/d
Number of subjects: 245
Study: 23718222

Group type: EXPERIMENTAL
Intervention: Spanish Diabetes Self-Management Program (SDSMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care according to clinical guidelines for DM2
Number of subjects: 0
Study: 21189274

Group type: EXPERIMENTAL
Intervention: Normal food intake
Number of subjects: 58434
Study: 19317163

Group type: EXPERIMENTAL
Intervention: Xiaoyu Zhixue Tablet (XYZXT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Western medicine (adrenosin, vitamins C, K and P)
Number of subjects: 98
Study: 14510743

Group type: EXPERIMENTAL
Intervention: Valproic acid (1 g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10424639

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1155
Study: 7784148

Group type: EXPERIMENTAL
Intervention: CO2 intraarterial subtraction angiography (IADSA) in group A (proper hepatic artery)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CO2 intraarterial subtraction angiography (IADSA) in group B (segmental hepatic artery)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CO2 intraarterial subtraction angiography (IADSA) in group C (peripheral inferior phrenic artery)
Number of subjects: 31